All Pharma News
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI

Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI
BUSINESSWIRE
18 Mar 2024
Share Share
Lundbeck`s new CEO van Zyl talks long-term growth plan

Lundbeck`s new CEO van Zyl talks long-term growth plan
FIERCE PHARMA
23 Jan 2024
Share Share
Lundbeck encourages migraine patients to ‘Say Yep’ to its IV-infused med

Lundbeck encourages migraine patients to ‘Say Yep’ to its IV-infused med
Beth Snyder Bulik ENDPTS
19 Jan 2024
Share Share
Lundbeck, Otsuka dial down the drama for Rexulti agitation ad

Lundbeck, Otsuka dial down the drama for Rexulti agitation ad
Nick Paul Taylor FIERCE PHARMA
13 Oct 2023
Share Share
Enforcement Report - Week of September 6, 2023

Enforcement Report - Week of September 6, 2023
FDA
06 Sep 2023
Share Share
AbbVie, Lundbeck ask FDA to revise draft guidance on migraine drugs

AbbVie, Lundbeck ask FDA to revise draft guidance on migraine drugs
Lia DeGroot ENDPTS
01 Aug 2023
Share Share
Otsuka, Lundbeck`s campaign spotlights agitation symptoms in Alzheimer’s disease

Otsuka, Lundbeck`s campaign spotlights agitation symptoms in Alzheimer’s disease
Beth Snyder Bulik ENDPTS
26 Jul 2023
Share Share
Lundbeck hires UCB neurology exec as new CEO

Lundbeck hires UCB neurology exec as new CEO
Angus Liu FIERCE PHARMA
27 Jun 2023
Share Share
Lundbeck to Present New Clinical and Real-World VYEPTI® (eptinezumab-jjmr) Data

Lundbeck to Present New Clinical and Real-World VYEPTI® (eptinezumab-jjmr) Data
BUSINESSWIRE
15 Jun 2023
Share Share
Otsuka & Lundbeck Announce US FDA Approval of (sNDA) for REXULTI®

Otsuka & Lundbeck Announce US FDA Approval of (sNDA) for REXULTI®
BUSINESSWIRE
10 May 2023
Share Share